NCT04982991View on ClinicalTrials.gov

Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

October 11, 2021

Study Completion Date

October 11, 2021

Conditions
Multiple Sclerosis Healthy Subjects
Interventions
DRUG

RIPK1 inhibitor

Capsule Oral

Trial Locations (1)

HA1 3UJ

Investigational Site Number :8260001, Harrow

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT04982991 - Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants | Biotech Hunter | Biotech Hunter